Ann: Appointment of Executive Director & FDA Pre-Ind Meeting, page-15

Not long before it sky rockets and the reasons why

1., Dr Tony Keating new guy on the block but associated with Brian Leedman at ressap,brian leedman was with NSB and went over to help with the takeover of ressap.

2.Dr Keating would not have come to nsb unless he sees a very bright future as he did with ressap.

3.Glaucoma treatment was shown to reverse eye damage in 2019,,,,

Due to EmtinB’s capacity to promote optic nerve regeneration, NeuroScientific believes it could be the first available disease-modifying treatment of glaucoma.

“The potential for reversing the glaucoma-induced damage to the optic nerve is being heralded as a major potential health breakthrough by ophthalmologists,” the company stated.

According to NeuroScientific, the ophthalmic market is valued at around $25 billion per annum and is forecast to grow to $5.3 billion per annum worldwide during the next three years.

4.Fda approval will put this in a leading class and a viable takeover target.

5.will be over 10c in days.